ELSHADAY TEFERI: Open Payments
NPI 1689215527 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,294 in 157 payments from 17 companies in 2025. Trend: 2023 $3,661 · 2024 $3,353 · 2025 $3,294
Food & beverage: $3,294
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $409 |
| Lundbeck LLC | 21 | $383 |
| Alkermes, Inc. | 17 | $302 |
| Axsome Therapeutics, Inc. | 13 | $295 |
| Vanda Pharmaceuticals Inc. | 11 | $291 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $249 |
| Teva Pharmaceuticals USA, Inc. | 10 | $247 |
| Bausch Health US, LLC | 13 | $180 |
| Neurocrine BioSciences, Inc. | 6 | $172 |
| Janssen Pharmaceuticals, Inc | 6 | $169 |
Products named: VRAYLAR, ARISTADA, FANAPT, CAPLYTA, Auvelity, REXULTI, INGREZZA, COBENFY.
Industry payments across MD — which companies pay providers there.
